BeOne Medicines revenue and financials
$362.78Change from previous close: +0.31%Absolute change: +$1.13
In the fiscal year ended December 2025, BeOne Medicines reported revenue of $5.34B (+40.23% year over year). Net income was $286.93M, a net margin of 5.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +40.23%
- 2025 vs 2024
- Net margin
- 5.4%
- 2024: -16.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 463 | 201 | 417 | 403 | 264 | 44.1 | 75.2 | 188 | -95.6 | -309 | -396 | 117 |
| Depreciation and amortization | 38.9 | 39.4 | 34.4 | 35.7 | 29.9 | 31.6 | 49.1 | 70.1 | 23.8 | 24.1 | 83.9 | -40.7 |
| Capital expenditure | -27.5 | -40.8 | -37.5 | -48.1 | -43.8 | -56.4 | -92.5 | -134 | -110 | -157 | -125 | -177 |
| Investing cash flow | -49.4 | -45.5 | -38.3 | -49.3 | -66.6 | -122 | -93.6 | -134 | -111 | -210 | -338 | 78.1 |
| Financing cash flow | -6.1 | 68.6 | 96.9 | 961 | 35.0 | -33.8 | -4.5 | 12.7 | 23.0 | 162 | 381 | -112 |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | -15.4 |
| Share repurchases | — | — | — | — | -24.2 | — | — | — | — | — | — | — |
| Debt issued | 0.0 | 58.2 | 863 | 0.0 | 142 | 80.0 | 544 | — | 182 | 151 | 500 | 0.8 |
| Debt repaid | -17.1 | -7.6 | -784 | -4.3 | -115 | -177 | -557 | -3.6 | -168 | -3.6 | -155 | -97.3 |
| Effect of exchange rates | 19.8 | 19.3 | 23.2 | 9.9 | 23.5 | 3.5 | -51.7 | 28.3 | -5.9 | -22.4 | -14.3 | 56.9 |
| Net change in cash | 427 | 244 | 499 | 1,324 | 255 | -108 | -74.7 | 95.5 | -190 | -379 | -367 | 140 |
| Free cash flow | 435 | 161 | 380 | 354 | 220 | -12.3 | -17.3 | 54.7 | -206 | -465 | -521 | -60.0 |
| Levered free cash flow | 215 | 43.7 | 366 | 254 | 180 | -145 | 4.2 | 139 | -122 | -392 | 71.8 | -493 |